In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Shire gets ex-US rights to three Amicus compounds; terminated

Executive Summary

Amicus Therapeutics (developing oral drugs to treat various genetic diseases) licensed Shire PLC's Shire Human Genetic Therapies worldwide rights outside the US to its Phase II Amigal (migalastat) for Fabry disease, Phase II Plicera (isofagomine tartrate) for Gaucher disease, and Phase I AT2220 (deoxynojirimycin) for Pompe disease.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies